The trial will test four dose levels and include up to 18 patients with advanced, FLT3-expressing acute myeloid leukemia.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...